Woodline Partners’s Sutro Biopharma STRO Stock Holding History

Woodline Partners’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.4M	Buy	+457,441	New	+$8.27M	0.04%	478
2022 Q4	–	Sell	-7,395	Closed	-$410K	–	840
2022 Q3	$410K	Hold	7,395	–	–	0.01%	606
2022 Q2	$385K	Buy	7,395 +3,517	+91%	+$196K	0.01%	587
2022 Q1	$319K	Buy	+3,878	New	+$369K	0.01%	531
2021 Q4	–	Sell	-21,951	Closed	-$4.15M	–	781
2021 Q3	$4.15M	Hold	21,951	–	–	0.07%	283
2021 Q2	$4.08M	Buy	21,951 +354	+2%	+$69.3K	0.08%	242
2021 Q1	$4.92M	Buy	21,597 +3,379	+19%	+$802K	0.11%	197
2020 Q4	$3.96M	Buy	+18,218	New	+$3.02M	0.1%	169

Other funds holding STRO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners's STRO Position: Q1 2026 in Review

Woodline Partners opened a new position in Sutro Biopharma (STRO) in Q1 2026: 457,441 shares worth $11.4M. The stake represents 0.04% of the portfolio and ranks #478 among its holdings. This is a return to the name: Woodline Partners previously reported a position in STRO as recently as Q3 2022.

Woodline Partners first reported a position in STRO in Q4 2020 and has held it in 8 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

Woodline Partners held 457,441 shares of Sutro Biopharma worth $11.4M as of Q1 2026.
Sutro Biopharma was a new Woodline Partners position in Q1 2026.
Sutro Biopharma made up 0.04% of Woodline Partners's portfolio in Q1 2026, its #478 holding.
Woodline Partners first reported a position in Sutro Biopharma in Q4 2020 and has held it in 8 quarters since.
78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.